The purpose of this study is to evaluate the safety and effectiveness of Retroperitoneal Lymph Node Dissection (RPLND) as a treatment for seminoma that has spread to the lymph nodes in the retroperitoneum. The retroperitoneum is an area in the body located behind the intestines and is often the first place where seminoma spreads. Seminoma is a type of testicular cancer, and RPLND is a surgical procedure to remove these lymph nodes.
In this study, participants will undergo a surgical procedure called RPLND to treat testicular seminoma. This surgery involves the removal of lymph nodes in the retroperitoneum and may result in fewer long-term side effects, such as the risk of developing a second cancer, heart disease, metabolic issues, or lung disease.
- Who can participate: Men with stage IIA pure seminoma or stage I pure seminoma with isolated retroperitoneal relapse are eligible if they have lymphadenopathy in the retroperitoneum and negative chest imaging for metastasis within six weeks before RPLND. The primary tumor must have been removed through radical inguinal orchiectomy with negative surgical margins.
- Study details: Participants will undergo a surgical procedure called RPLND to remove lymph nodes in the retroperitoneum. This surgery aims to treat testicular seminoma and may result in fewer long-term side effects.
